A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Status:
RECRUITING
Trial end date:
2035-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced breast, colorectal, prostate, and endometrial cancer. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.